Member Info for sadoldgit

I welcome that correction HbD.

Are all of us here looking st values of circa 750 to 1.5 billion?

Thst is a 25 to 50 fold increase.

Deucravacitinib 4 billion?

Is Deucravacitinib over priced or is Sareum underpriced.

The writing was on the wall st end if phase2 studies in Psoriasis.

How long had this interested party been pulling the strings.

It is a first off.

Mot necessarily the best of.

Nearest competitor is Riovant either Brepicitinib.

Withdrawn from further studies in Pdoriasis as has off target effects, Oh dear

C79 made a point of tge commercialisation value attributed yo Riovant around 2.5 billion in current form.

With regards to safety it can be considered inferior to 1801 without doubt.

We can use a 1802 as a backup to 1801 but not use 1801 as backup for 1802. Similar compounds ?

Odd that Tim now COO concentrating on 1802 with translational studies snd now we looking at possible 1803.

I'd it s case of a company is now driving the potential of our compounds?

Similarities here with GSK and Sierra Oncology.

Change of CEO less than two years before company was bought out primarily for Momolotinib. Both WEE1 and Chk1 inhibitor placed on the back burner.

1.9 billion for momo!

The donkey work is nearing completion with 1801.

What is there to stop it being fast tracked into areas with urgent unmet need?

All a kathe phatma looking at is thst it us satisfactory hor long term use

That is where the commercialisation value is.

As Tim pointed out many many moons ago, the threats are from new discovery treatments thst may out perform thst which is currently been developed.

A point was raised about AML.

I take it the individual realised that Aurora+ FLT3 was designed to treat AML. The downside of course was the solubility issues that arose when formulating an oral compound.

However we were never told if it were at the point creating a solute or the process of a solid being absorbed through the intestine which of course needs to be in a soluble state.

Sareum, although they are not biologists will know via SKIL what us required through interactions and signalling pathways which ones they are to treat an indication.

They will also be aware that the binding affinity plays an important role. Take note of that as we inhibit Jak1 which is impossible to be 100% selective over Jak 2 and Jak 3 yet in 1801 no Jak2 activity was detected.

I am of the opinion here thst there is a preferential bonding here related to affinity.

We have deuterium instead of Hydrogen in one of the molecules supposedly to increase binding affinity as far as l.can see. However not all isotopes of hydrogen are deuterium in individual molecules.

Big thing made by BMS in the use of deuterium atoms in Deucravacitinib. I reckon that6 is where it gets it's name from. WOW.

Little Sareum been developing for years and made no big deal of it.

I fid try and engage Tim on this subject last December. Tim.eould not e

With all due respect Hemo did mot have the funds to progress. After good results 200% gained in a few days and then lo and behold partnership is signed and bang up another 100% looking at a 550% increase over all.

We have been conditioned to believe that our shares are worth next to nothing and this is the base to work from.

I put a few bob in IMM last Thursday. Up over 60% so will sell and add to tge mother of all undervalued biotechnology companies.

Regards

Good morning Bailiff,

In the past when expecting good news tge wheel has come off so as to speak.

Hemo has circa 22% price increase on news of people taking their options. Sareum has the same snd the price falls.

Once long term toxicology results are known then we should escalate rather rapidly North.

In my opinion for what it is worth this exercise is merely a formality. Akin to having your car serviced by a main dealer then putting your car in fir an MOT just afterwards.

It us all down to preparation and attention to detail.

An interesting point of course is 1802.

It has patent coverage for immino therapy .

It may very well be suitable for such indications at CD and UC.

The advantage here of course is the higher jak content but still of course a 4 fold selectively of Tyk2 over the other jaks.

As gas beeb mentioned before 1802 designed to be compatible with many other treatments as such that 1892 may become the major treatment as opposed to supportive.

Most of us here already know that, this for the benefit of those that do not and the source of information is raven from compound description in the application for a patent protection and approval.

Regards and have a good day all.

Take a look st Hemo. An RNS fir partnership.

No reason to suggest we cannot follow the same trajectory on good tox results and impending partnership as a direct result of satisfactory results.

If we look at Hemo current price 2 x pre consolidation price and that would give us 12 p per share old money or 6 pounds a share new.

Circa market cap of 800 million.

If it does not appear realistic neither did a market cap of 300 million dropping down to 8 million.

Regards

Pretty sure you will ok soon Matty. I am in the process of being hammered by the tsxnsn at the moment. 46k tax for this year..

Offered some work in the dessert 140k all expenses paid and no tax.

Tax man tells me l am not entitled to tax relief on expenses away from home as he says employer pays me. Employer has not reimbursed my expenses!

Will employ tax specialist to resolve issue.

This country is stuffed!

Trades are very up and down on Hemo and IMM

Very heavy swings in price and many delayed trades showing.

Share price volatile and l would suggest movements manipulated by heavy buys and sells by financial institutions ir groups of individuals.

We will not be immune from this of course.

With regards to Black boxed warnings for 1801 you can remove this outcome as relates to associated problems cardio problems associated with JAK2 inhibition that was not observed detected in SAD and MAD phase 1 clinical trial.

The purpose for the long term toxicology trial is to find if it is suitable for long term use.

The capsule formulation is also to be improved on which is already impressive results.

Also bare in mind tgat whilst undergoing a trial it takes time for data to be collected after each branch of periods of differing dosages.

Not been overly successful in predicting dates in the past but would put RNS relating to toxicology study at first week in October.

Regarding presentation I'm a journal l can't see that happening and in reality cannot cause any problems. These parties interested in our compounds have to need for a report in a journal.

They will know more than what is in the journal anyway!

Regards

Brepro news interesting. As Tim says our mist advanced competitor.

https://investor.roivant.com/news-releases/news-release-details/roivant-reports-financial-results-first-quarter-ended-june-30-1

'Momelotinib Market size is estimated to be USD 100 Million in 2024 and is expected to reach USD 500 Million by 2033 at a CAGR of 20% from 2026 to 2033.

22 Jul 2025'

The biggest increase would be is when any of Sareims compounds obtain FDA approval or similar

On good tox results there really is no reason why the compound cannot be fast tracked into areas of high unmet need.

Deucravacitinib 4 billion at end of phase 2 with reasonable results in Psoriasis.

Theoretically 1801 should out perform Deucravacitinib in Psoriasis.

Is 400 million an under value for 1801 taking into account a value of one tenth of Deucravacitinib?

I have a feeling that there has been a bit of share selling on Hemo with some share purchases here.

Potnak. There iss no need to notify us if the trial is finished, however on receipt of preliminary reports Sareum very highly likely to release RNS.

Thst is my take on it.

MTD will not take more than a few weeks..

30 times max therapeutic already done with no Indication major adverse event in sight.

Take into consideration here that this rose escalation will be given in my per kilo body weight

These ten to be far higher doses than on humans to give a safety margin.

Maximum therapeutic dose set at 1000 mg per day.

I did put a figure of 400 million at near end of phase 2 1801 on providing progress. Thst was around mid 2022.

Mocked and ridiculed by some. However, I am inclined to think that this is the minimum value thst can be placed on decent toxicology results as we sit now.

All in all a valuation of between 400 to 1 billion as we sit with acceptable toxicity results.

GsK paid 1.9 billion for SO primarily for Momolotinib with a somewhat limited commercialisation potential.

Share holders were up on arms as claimed company worth far more than the question.9 billion with the the pipeline they had.

Great to see tge likes of Hemo increasing in value.

At 880p in effect only circa 50% increase in SP as they did have a consolidation of shares 400 to 1..

Whilst not certain l feel ot will not be long before we hit 3 digit numbers on SP post toxicology results. Preliminary results that wil be.

Regards to all.

3 months into toxicology study. Time and co will know jow it us progressing.

Some sort of attempt at MTD to.

30 x therapeutic dosage with no observed signs anywhere near of reaching MTD.

Time did say wee msy have to go to 100 times.

But l doubt they attempted that as Tim was saying would need to manufacture more compound to the point that it is more than would be used fir laboratory tests.

Be great if they were carrying this out.

Tge added advantage here is it would mot take long to establish and am 99.9% certain the result will already be known.

As has been posted here before the toxicology reports are of tge upmost importance as such cannot be over emphasised.

A phase2 Tyk2 Jak1 compound thst fies not suffer the adverse side events if JAK 2 activity.

A billion is most certainly not out of the question.

M cap is low at 30 million.

As can be seen by the progress of Hemo there is appetite for investment on good results.

737 is rather difficult to comprehend exactly whst us happening.

Would it well be thst Ssrrum have been requested not to on licence 737? Look whst happened to 737 band wee 1 inhibitor when SO were taken over by GSK.

Very odd that both were well and truly placed on the back burner circa 6 to 9 months before news of formal.offer.

As for GSK phoning up 6 weeks before trying to scratch a deal l say big hairy cobblers.

Shall we we put to the vote those thst believe we are being well and truly steered by a 3rd party possibly large pharma or just a peculiar vhsnge in firection by the Sareum BoD.

Formal offers have to be announced.

Now there were offers made for SO that fell very short of what GSK eventually offered.

With regards to zTim saying ' look forward to seeing you next year' Tim also stated that whilst they were looking to on licence if the.right offer came along at the right price they would accept as they were not getting any younger.

Any interested party cannot realistically make an offer until toxicology studies completed.

They may well have a pro rata price dependant on results and what else have you in tge pipeline.

Also take into account that 1892 has patent coverage to treat auto immune.

Very surprised that a lead candidate has not been selected.

Bbb and CNS all tge rage at the moment

Should deliver similar results as Hemo with regards progress and sentiment.

Regards

Good morning PCS1954.

Am in agreement with you regarding SP.

A deal of some sort will arise soon with value placed on just how good toxicity results are.

May well lead to collaboration or partnership for 1801.

That does leave 1802 and phenomenal potential of (1803 ?) in BBB and CNS. It is early stages and the complexity in indications of the CNS are immense.

What l do see and l will not go into depth here is a potential for development in brain trauma as opposed to conditions of the brain eg Parkinsons and dementia.

There is a difference here.

AI can speed up process to indicate candidates.

The object here is as we have already identified a compound that indicates significant potential it is the optimisation that is all important.

The treatment for CNS illnesses world wide is around 1.8 trillion dollars a year.

Only a tiny percentage of this is on medication.

Regards

About 6 weeks behind Hemo would do nicely. They increased another 60% today.

Hood to see a hammered AIM biotechnology make it through the dross of the past 3 years and reach fruition.

It certainly us a crucial time with regards to Sareum.

All boils down to jow good tge long term toxicology studies go. I do not forsee a problem at all. Not a case of being good just a case of how good.

Efficacy should be fine and indications know to Sareum and potential interested parties.

As long as toxicology study satisfactory then no compromise on potential of efficacy.

No dreaded off target JAK2 inhibition in SAD and MAD cohorts.

I think Tom and John have options of 2.4 and 1 .3 million respectively. I cannot see them buying them yet until st least past 50p per share.

CHK1 may also be of use in diseases of the central nervous system. Taken from a link from 2022

Chk1 is involved in central nervous system (CNS) diseases, with its activation linked to cognitive dysfunction in Alzheimer's disease and spinal cord injuries, as well as contributing to neuron loss in these conditions. Inhibition of Chk1 has shown promise in mitigating these pathologies by improving neuron survival and function, suggesting a potential therapeutic strategy for CNS disorders.

There is a very very long read on therapeutics of a ChK1 inhibitor below.

Jeez, even goes on longer than some of my posts.

https://pmc.ncbi.nlm.nih.gov/articles/PMC6727643/

It is not new however tge realisation that CHK1 may benefit heart problems relying to damaged cells.

From 2019

'Hyperproliferative pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension and animal models display elevated levels of DNA damage and exhibit constitutive activation of the ATR (ataxia telangiectasia and Rad3–related)/CHK1 (checkpoint kinase 1) pathway.

In vitro, pharmacological or molecular inhibition of CHK1 exacerbates DNA damage and reduces pulmonary arterial hypertension–pulmonary artery smooth muscle cell proliferation and resistance to apoptosis.

Lung-specific targeting of CHK1 is associated with histological and hemodynamic improvement in 2 rat models of pulmonary arterial hypertension.'

Regards

Great kind Krone.

Application for patent protection needed here me thinks.

Our pipeline gets all the more impressive.

Regards

1.5 billion?

What are they going to get for that?

Is that 1.5 billion with milestones?

It is achievable but before people start putting pen to paper they will at least need know toxicology even preliminary results.

If there is more than one party interested of which l think there is then Sareum can choose.

I take it when referring to the unknown Chinese pharma you are referring to Aurora FLT3.

Tgat had a problem with solubility issues.

I very much doubt that this would be down to the skill platform as that would look at kinases and relevant association of molecule with associated Jsk target.

Using AI will not tell you if it will work. All it us in effect doing is looking at probabilities. Time saving in a sense as can filter out some of the lowest probability of success.

We are looking at binding energies and yge affinity if molecules.

Ai did not produce 1801!

It has its uses and thst os interpreting data that is fed into it and can process far quicker than the human brain.

4 months I am assuming you infer that us likely to be deal time?

End of September looking at completion of toxicology studies. I don't think an interested party in 1801 is going to wait for results of new preclinical CNS compound to put an offer in.

Unless of course someone wants the whole lot.

Time will tell! All getting very very exciting